1. Home
  2. EVG vs PYXS Comparison

EVG vs PYXS Comparison

Compare EVG & PYXS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Eaton Vance Short Diversified Income Fund Eaton Vance Short Duration Diversified Income Fund of Beneficial Interest

EVG

Eaton Vance Short Diversified Income Fund Eaton Vance Short Duration Diversified Income Fund of Beneficial Interest

N/A

Current Price

$10.34

Market Cap

136.9M

Sector

Finance

ML Signal

N/A

Logo Pyxis Oncology Inc.

PYXS

Pyxis Oncology Inc.

N/A

Current Price

$1.73

Market Cap

141.3M

Sector

Health Care

ML Signal

N/A

Company Overview

Basic Information
Metric
EVG
PYXS
Founded
N/A
2018
Country
United States
United States
Employees
N/A
N/A
Industry
Investment Managers
Biotechnology: Pharmaceutical Preparations
Sector
Finance
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
136.9M
141.3M
IPO Year
2004
2021

Fundamental Metrics

Financial Performance
Metric
EVG
PYXS
Price
$10.34
$1.73
Analyst Decision
Strong Buy
Analyst Count
0
10
Target Price
N/A
★ $8.22
AVG Volume (30 Days)
52.6K
★ 797.9K
Earning Date
01-01-0001
11-05-2026
Dividend Yield
N/A
N/A
EPS Growth
N/A
★ 3.03
EPS
★ N/A
N/A
Revenue
N/A
★ $13,858,000.00
Revenue This Year
N/A
N/A
Revenue Next Year
N/A
$14,188.99
P/E Ratio
N/A
★ N/A
Revenue Growth
★ N/A
N/A
52 Week Low
$9.78
$1.03
52 Week High
$11.30
$5.55

Technical Indicators

Market Signals
Indicator
EVG
PYXS
Relative Strength Index (RSI) 51.43 40.04
Support Level $9.99 $1.59
Resistance Level $10.95 $1.84
Average True Range (ATR) 0.19 0.14
MACD -0.00 0.03
Stochastic Oscillator 55.92 45.74

Price Performance

Historical Comparison
EVG
PYXS

About EVG Eaton Vance Short Diversified Income Fund Eaton Vance Short Duration Diversified Income Fund of Beneficial Interest

Eaton Vance Short Duration Diversified Income Fund is a diversified, closed-end management investment company. Its primary investment objective is to provide a high level of current income with a secondary objective of seeking capital appreciation to the extent consistent with its primary goal. The portfolio of investments consists of business equipment and services, automotive, cable and satellite television, chemicals and plastics, food products, and other areas.

About PYXS Pyxis Oncology Inc.

Pyxis Oncology Inc is a clinical-stage oncology company focused on developing therapies for patients with solid tumors, with an initial emphasis on head and neck squamous cell carcinoma. Its product candidate, micvotabart pelidotin (MICVO, formerly PYX-201), is an investigational antibody-drug conjugate that targets extradomain-B fibronectin (EDB+FN), a component of the tumor extracellular matrix that is expressed in tumors and minimally present in normal tissues. MICVO consists of a fully human monoclonal antibody linked to a microtubule inhibitor payload, designed to bind within the tumor microenvironment and release its payload to kill cancer cells directly, affect nearby cells through a bystander effect, and induce immunogenic cell death, supporting enhanced anti-tumor activity.

Share on Social Networks: